Genetic advancements in breast cancer treatment: a review by Marzieh Shokoohi, Sadaf Sedaghatshoar, Homaira Arian, Milad Mokarami, Fatemeh Habibi, Fatemeh Bamarinejad

“…CRISPR/Cas9 enables precise gene editing to correct mutations in oncogenes like HER2 and MYC, directly addressing tumor growth and immune evasion. …”
Get full text

The role of PM2.5 exposure in lung cancer: mechanisms, genetic factors, and clinical implications by Chi-Yuan Chen, Kuo-Yen Huang, Chin-Chuan Chen, Ya-Hsuan Chang, Hsin-Jung Li, Tong-Hong Wang, Pan-Chyr Yang

“…PM2.5 can increase oxidative stress and inflammation, induce genetic alterations and activation of oncogenes (including the epidermal growth factor receptor, EGFR), and contribute to lung cancer progression. …”
Get full text

Drug delivery systems for oral cancer treatment: A patent perspective by Mohamed Hassan Dehghan, Abrar Abdul Malik Siddiqui

“…The disease progresses through multiple genetic and epigenetic alterations involving tumor suppressors like p53, p16, and FHIT, along with oncogenes like EGFR, c-yc, K-ras, int-2, PRAD-1, and bcl leading to the development of premalignant lesions and subsequent tumors. …”
Get full text

Unraveling the Molecular Nexus between GPCRs, ERS, and EMT by Niti Kumari, Somrudee Reabroi, Brian J. North

“…Here, we will discuss the interplay in GPCR-ERS linked to the EMT process of cancer cells, with a particular focus on oncogenes and molecular signaling pathways.…”
Get full text

Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience by Ezgi Genç Erdoğan, Tülin D. Yalta, Nuray Can, Necdet Süt, Ebru Taştekin, Ufuk Usta, Fulya Öz Puyan, Fatma E. Usturalı Keskin, Busem B. Kurt

“…Conclusion: This study's findings regarding different molecular types of UCS and information on oncogenesis of UCS can provide inferences for targeted therapies in the future by identifying targetable mutations representing early oncogenic events and thereby contribute toward further studies on this subject.…”
Get full text

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma by Son Tran, Patrick Sipila, Melanie M. Frigault, Beatrix Stelte-Ludwig, Amy J. Johnson, Joseph Birkett, Raquel Izumi, Ahmed Hamdy, Ranjan Maity, Nizar J. Bahlis, Paola Neri, Aru Narendran

“…Enitociclib inhibited the phosphorylation of the carboxy-terminal domain (CTD) of RNA polymerase II at Ser2/Ser5 and repressed the protein expression of oncogenes c-Myc, myeloid cell leukemia-1 (Mcl-1), and proliferating cell nuclear antigen (PCNA) in MM cells. …”
Get full text

Purine-rich element binding protein alpha: a DNA/RNA binding protein with multiple roles in cancers by Shiyi Yu, Chengyang Jiang, Yawen Yang, Fei Cheng, Fangchen Liu, Chang Liu, Xue Gong

“…Most recently, several studies have revealed that PURα is dysregulated in multiple cancers, such as breast cancer (BC) and esophageal squamous cell carcinoma (ESCC). The oncogenic or tumor-suppressive functions of PURα are realized via regulating RNA/protein interaction, mRNA translation, formation of stress granules (SGs), and transcriptional regulation of several oncogenes and tumor suppressors. …”
Get full text

Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short Review by Zhang C, Yang C, Shi Q

“…Mutated p53 protein may have some pro-oncogenic impact, and the variations may change tumor inhibitors into oncogenes. …”
Get full text

lncRNAs: the unexpected link between protein synthesis and cancer adaptation by Mila Gugnoni, Manoj Kumar Kashyap, Kishore K. Wary, Alessia Ciarrocchi

“…On the other hand, by prioritizing the synthesis of specific transcripts they help cancer cells to maintain high levels of essential oncogenes. In this review, we aim to discuss the most relevant evidence regarding the involvement of lncRNAs in translation regulation and to discuss how this specific function may affect cancer plasticity and resistance to stress. …”
Get full text

Super-enhancers in hepatocellular carcinoma: regulatory mechanism and therapeutic targets by Xuejin Lu, Meizi Zhu, Xingyue Pei, Jinhu Ma, Rui Wang, Yi Wang, Shuwen Chen, Yan Yan, Yaling Zhu

“…In tumor cells, SEs intricately regulate the expression of oncogenes and pivotal cancer-associated signaling pathways, offering significant potential for cancer treatment. …”
Get full text

AEBP1 Promotes Glioblastoma Progression and Activates the Classical NF-κB Pathway by Kai Guo, Lei Song, Jianyong Chang, Peicheng Cao, Qi Liu

“…AEBP1 could upregulate the level of IκBα phosphorylation, decrease IκBα expression, activate the NF-κB signaling pathway, and promote the expression of downstream oncogenes. Conclusion. Upregulated AEBP1 in GBM promotes GBM cell proliferation, migration, and invasion and facilitates tumor growth in vivo by activating the classical NF-κB pathway.…”
Get full text

Deciphering the dose-dependent effects of thymoquinone on cellular proliferation and transcriptomic changes in A172 glioblastoma cells. by Rachana Pandey, Purushothaman Natarajan, Umesh K Reddy, Wei Du, Cristian Sirbu, Moussa Sissoko, Gerald R Hankins

“…It downregulated several potential oncogenes (e.g., AEBP1, MIAT) and genes linked to GBM proliferation and migration (e.g., SOCS2, HCP5) while modulating Wnt signaling and up-regulating tumor suppressor genes (e.g., SPRY4, BEX2). …”
Get full text

miR-370-3p as a Novel Biomarker Promotes Breast Cancer Progression by Targeting FBLN5 by Jiahui Mao, Lingxia Wang, Junying Wu, Yichun Wang, Huiyan Wen, Xueming Zhu, Bo Wang, Huan Yang

“…In cancer, miRNAs can be divided into oncogenes or tumor suppressors on the basis of their functions in the carcinogenic process. …”
Get full text

High Ano1 expression as key driver of resistance to radiation and cisplatin in HPV-negative head and neck squamous cell carcinoma by Solenne Bourdier, Anne-Sophie Fisch, Keziban Merve Alp, Ridhima Das, Philipp Mertins, Ingeborg Tinhofer

“…Abstract Human papilloma virus-negative head and neck squamous cell carcinoma (HNSCC) frequently harbors 11q13 amplifications. Among the oncogenes at this locus, CCND1 and ANO1 are linked to poor prognosis; however, their individual roles in treatment resistance remain unclear. …”
Get full text

Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Clinicopathologic Analysis with Evaluation of the E-Cadherin/β-Catenin Complex and Associated Genetic Alterations by Maria Del Valle Estopinal, Lavinia P. Middleton, Bita Esmaeli, Keyur P. Patel, Sara Nowroozizadeh, Michelle D. Williams

“…Our results suggest an abnormality in the convergence of E-cadherin/β-catenin pathways which may promote tumorigenesis by inducing expression of oncogenes such as Cyclin D1 and C-Myc. Mutations in CDH1, PIK3CA, and TP53 genes could induce E-cadherin dysfunction which takes part in the development and progression of this malignancy.…”
Get full text

Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology by Ming-Huang Chen, Wan-Shan Li, Bin-Chi Liao, Chiao-En Wu, Chien-Feng Li, Chia-Hsun Hsieh, Feng-Che Kuan, Huey-En Tzeng, Jen-Fan Hang, Nai-Jung Chiang, Tse-Ching Chen, Tom Wei-Wu Chen, John Wen-Cheng Chang, Yao-Yu Hsieh, Yen-Lin Chen, Yi-Chen Yeh, Yi-Hsin Liang, Yu-Li Su, Chiung-Ru Lai, James Chih-Hsin Yang

“…Results: The joint statement proposes key recommendations: (1) MTB discussions encompass diverse molecular analyses including next-generation sequencing (NGS), RNA sequencing, whole-exon sequencing, and whole-genomic sequencing addressing relevant genomic changes, tumor mutation burden, microsatellite instability, and specific biomarkers for certain cancers. (2) MTB meetings should involve multidisciplinary participants who receive regular updates on NGS-related clinical trials. (3) Prioritize discussing cases with unique clinical needs, gene alterations lacking treatments, untreatable neoplasms, or oncogenes unresponsive to targeted therapies. (4) Base MTB discussions on comprehensive patient data, including genetics, pathology, timing of specimen collection, and NGS outcomes. (5) MTBs offer treatment recommendations: standard therapies, off-label use, clinical trials, genetic counseling, and multidisciplinary reviews. (6) MTB effectiveness can be gauged by member composition, case reviews, treatment suggestions, and patient outcomes. …”
Get full text

Epigenetic Regulation of Stromal and Immune Cells and Therapeutic Targets in the Tumor Microenvironment by Kang Liu, Yue Li, Minmin Shen, Wei Xu, Shanshan Wu, Xinxin Yang, Bo Zhang, Nengming Lin

“…Epigenetic machinery, governing the expression of core oncogenes and tumor suppressor genes in transformed cells, significantly contributes to tumor development at both primary and distant sites. …”
Get full text

Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapy by Qing Nian, Yan Lin, Jinhao Zeng, Yanna Zhang, Rongxing Liu

“…Wilms tumor 1 (WT1) is a multifaceted protein with dual functions, acting both as a tumor suppressor and as a transcriptional activator of oncogenes. WT1 is highly expressed in various types of solid tumors and leukemia, and its elevated expression is associated with a poor prognosis for patients. …”
Get full text

PD-L1 Expression and CD8+ T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer by Yangyang Wang, Chunchao Zhu, Wei Song, Jun Li, Gang Zhao, Hui Cao

Get full text

Function of vasohibin-2 and the mechanism of alternative splicing in triple-negative breast cancer by WANG Wei, WANG Hongli, ALIBIYATI·i Ain, YILIYAER· Rousu, NUER AYI, YANG Liang

“…Genes with significantly altered alternative splicing levels due to VASH2 overexpressed were enriched in cell cycle and p53 signaling pathways.Conclusion·VASH2 regulates the alternative splicing of TNBC oncogenes and promotes TNBC occurrence and development.…”
Get full text